Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

ResMed Inc Stock Research

RMD

136.61USD+0.32(+0.23%)Market Closed
Watchlist

Market Summary

USD136.61+0.32
Market Closed
0.23%

RMD Alerts

  • 2 major insider sales recently.

RMD Stock Price

RMD RSI Chart

RMD Valuation

Market Cap

20.1B

Price/Earnings (Trailing)

22.38

Price/Sales (Trailing)

4.76

EV/EBITDA

17.46

Price/Free Cashflow

35.02

RMD Price/Sales (Trailing)

RMD Profitability

EBT Margin

26.47%

Return on Equity

21.94%

Return on Assets

12.85%

Free Cashflow Yield

2.86%

RMD Fundamentals

RMD Revenue

Revenue (TTM)

4.2B

Revenue Y/Y

22.66%

Revenue Q/Q

0.46%

RMD Earnings

Earnings (TTM)

897.6M

Earnings Y/Y

17.74%

Earnings Q/Q

-1.22%

Price Action

52 Week Range

136.22242.42
(Low)(High)

Last 7 days

-6.0%

Last 30 days

-15.7%

Last 90 days

-36.4%

Trailing 12 Months

-35.5%

RMD Financial Health

Current Ratio

3.07

Debt/Equity

0.4

Debt/Cashflow

0.34

RMD Investor Care

Dividend Yield

1.29%

Dividend/Share (TTM)

1.76

Shares Dilution (1Y)

0.45%

Diluted EPS (TTM)

6.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for RMD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
Farrell Michael J.
sold
-830,514
146
-5,675
chief executive officer
2023-09-15
Farrell Michael J.
acquired
327,788
57.76
5,675
chief executive officer
2023-09-01
Rider Michael J
sold
-4,028
161
-25.00
global general counsel
2023-08-25
BLAISE LUCILE
sold (taxes)
-62,903
165
-379
president, sleep & rc business
2023-08-17
Sandercock Brett
acquired
-
-
4,972
chief financial officer
2023-08-17
Farrell Michael J.
acquired
-
-
12,430
chief executive officer
2023-08-17
BLAISE LUCILE
acquired
-
-
4,113
president, sleep & rc business
2023-08-17
Ghoshal Kaushik
acquired
-
-
2,486
president, saas business
2023-08-17
Rider Michael J
acquired
-
-
2,247
global general counsel
2023-08-15
Farrell Michael J.
sold
-1,039,650
183
-5,675
chief executive officer

1–10 of 50

Which funds bought or sold RMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Halpern Financial, Inc.
new
-
12,455
12,455
-%
2023-09-21
Jefferies Group LLC
new
-
3,227,570
3,227,570
0.03%
2023-09-20
BARCLAYS PLC
added
157
53,053,000
86,847,000
0.06%
2023-09-12
Farther Finance Advisors, LLC
added
2.78
803
32,338
0.01%
2023-09-07
ST GERMAIN D J CO INC
new
-
4,910,790
4,910,790
0.26%
2023-09-05
Covenant Partners, LLC
unchanged
-
-2,287
1,020,180
0.37%
2023-09-01
Portside Wealth Group, LLC
new
-
321,422
321,422
0.06%
2023-08-28
Lavaca Capital LLC
unchanged
-
-1,423
634,743
0.19%
2023-08-24
Alberta Investment Management Corp
added
2.66
18,606
785,071
0.01%
2023-08-22
COMERICA BANK
new
-
9,000
9,000
-%

1–10 of 48

Latest Funds Activity

Are funds buying RMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RMD
No. of Funds

Schedule 13G FIlings of ResMed

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
wcm investment management, llc
2.6%
3,832,642
SC 13G/A
Feb 09, 2023
vanguard group inc
11.63%
17,028,881
SC 13G/A
Feb 07, 2023
blackrock inc.
9.4%
13,774,787
SC 13G/A
Feb 10, 2022
vanguard group inc
11.06%
16,119,963
SC 13G/A
Feb 10, 2022
wcm investment management, llc
6.21%
9,046,150
SC 13G/A
Feb 01, 2022
blackrock inc.
9.3%
13,561,224
SC 13G/A
Feb 10, 2021
wcm investment management, llc
6.09%
8,821,570
SC 13G/A
Feb 10, 2021
vanguard group inc
10.65%
15,439,844
SC 13G/A
Feb 01, 2021
blackrock inc.
9.7%
14,073,568
SC 13G/A
Feb 12, 2020
vanguard group inc
10.98%
15,790,293
SC 13G/A

Recent SEC filings of ResMed

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Sep 15, 2023
144
Notice of Insider Sale Intent
Sep 07, 2023
4
Insider Trading
Sep 01, 2023
144
Notice of Insider Sale Intent
Aug 29, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading

Peers (Alternatives to ResMed)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
108.3B
19.5B
3.38% 36.58%
39.99
5.57
10.36% 30.30%
101.2B
6.7B
-0.75% 50.83%
71.05
15.19
11.75% -0.66%
77.5B
13.4B
6.45% 36.39%
85
5.78
8.69% 3.17%
71.3B
19.0B
-4.29% 12.66%
44.09
3.79
0.46% -5.24%
42.3B
5.7B
-8.22% -17.24%
30.48
7.49
5.64% -4.53%
MID-CAP
9.5B
937.8M
-2.12% 37.22%
325.65
10.11
16.30% 250.21%
7.1B
616.6M
-12.54% -24.86%
29.24
11.56
69.52% 343.68%
5.1B
1.1B
-6.10% -12.07%
24.23
4.65
12.63% 50.85%
2.6B
452.1M
-21.20% -33.94%
-26.32
5.78
24.99% 24.09%
1.3B
790.3M
-27.09% -56.49%
-5.97
1.69
3.21% -1604.53%
SMALL-CAP
1.6B
421.8M
-15.15% 56.11%
-9.32
3.69
44.49% -2.43%
947.4M
780.7M
-7.75% -9.65%
-26.32
1.21
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
609.7M
162.9M
-27.67% -61.65%
-11.53
3.74
42.67% 12.82%

ResMed News

TheBull.com.au
18 Share Tips | 25th September 2023.
TheBull.com.au,
7 hours ago
InvestorsObserver
Rask Media
The Motley Fool Australia
InvestorsObserver

Returns for RMD

Cumulative Returns on RMD

11.6%


10-Year Cumulative Returns

12.9%


7-Year Cumulative Returns

4.7%


5-Year Cumulative Returns

-6.7%


3-Year Cumulative Returns

Risks for RMD

What is the probability of a big loss on RMD?

66.2%


Probability that ResMed stock will be more than 20% underwater in next one year

29.2%


Probability that ResMed stock will be more than 30% underwater in next one year.

0.4%


Probability that ResMed stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ResMed was unfortunately bought at previous high price.

Drawdowns

Financials for ResMed

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue5.2%4,2234,0163,7633,6243,5783,5393,4443,3493,1973,0913,0923,0282,9572,8922,7842,6992,6072,5252,4552,4052,340
Gross Profit4.2%2,3562,2612,1342,0592,0241,9931,9491,9071,8391,7981,8001,7651,7181,6711,6021,5501,4941,4341,3971,3721,335
Operating Expenses6.5%1,2241,1491,0891,0451,0241,006973958935912921909908963955943915829813799793
  S&GA Expenses5.7%874827781755738726704688670654666668677683675665645630614604600
  R&D Expenses5.0%288274264257254249238231225218213208202201197190181169159157155
EBITDA-100.0%-1,1811,1251,0741,0981,0951,0851,0581,0171,0431,020991928819771------
EBITDA Margin-100.0%-0.29*0.30*0.30*0.31*0.31*0.31*0.32*0.32*0.34*0.33*0.33*0.31*0.28*0.28*------
Interest Expenses-24.8%-47.38-37.98-28.48-24.09-22.31-58.74-47.45-35.71-23.63-52.20-48.05-43.62-39.3644.0046.0043.0036.0029.0024.0024.0028.00
Earnings Before Taxes3.6%1,1021,0631,000963960962953927884857830798733617563512519557-552521
EBT Margin-100.0%-0.26*0.27*0.27*0.27*0.27*0.28*0.28*0.28*0.28*0.27*0.26*0.25*0.21*0.20*------
Net Income4.0%898863809786779779522500475457699680622513455419405446450335316
Net Income Margin-100.0%-0.21*0.22*0.22*0.22*0.22*0.15*0.15*0.15*0.15*0.23*0.22*0.21*0.18*0.16*------
Free Cashflow-100.0%-421237325216364465411634748788698707514429------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.6%6,7526,7146,6765,1785,0964,9054,7354,7294,7284,5864,5734,6214,5874,5114,3544,1554,1084,0993,8603,0683,064
  Current Assets1.3%2,3682,3382,3252,0341,9311,7041,5471,5861,5751,4661,4511,5431,5231,4701,3001,1611,1451,1031,0641,0881,066
    Cash Equivalents0.0%228228253207274202194276295231256421463353204172147147149230189
  Inventory-1.3%9981,011989865744665592507457484475478417359378357350320297283269
  Net PPE1.7%538529523487498513478467463455459425417397408383387382382382387
  Goodwill-0.5%2,7702,7842,7671,9391,9361,9461,9511,9221,9281,9261,9101,9001,8901,8841,8711,8561,8561,9391,7591,1921,069
Liabilities-5.7%2,6222,7812,9381,7451,7351,6261,5891,7031,8421,8761,7081,9422,0902,2542,0962,0372,0352,0771,9041,1671,005
  Current Liabilities-0.4%759762733693689667621624912877577591603552500550556463436421511
  Short Term Borrowings0.0%10.0010.0010.0010.0010.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0011.00
  Long Term Debt-9.2%1,4311,5761,7917857656696687946437198141,0441,1641,3651,2881,2081,2591,3231,186518270
Shareholder's Equity5.0%4,1303,9333,7383,4333,3613,2793,1463,0262,8862,7092,8652,6792,4972,2562,2582,1172,0722,0211,9561,9002,059
  Retained Earnings4.0%4,2534,0883,9203,7603,6143,4803,3633,2223,0802,9413,0772,9542,8332,7122,6052,5012,4362,4212,3682,2962,432
  Additional Paid-In Capital2.5%1,7721,7291,7111,7021,6821,6451,6291,6441,6221,5871,5741,5881,5711,5341,5221,5301,5111,4761,4611,4641,451
Shares Outstanding0.1%147147147146146146146146146146145145145145144144144143143143143
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations29.5%693535370461351498577527737840884784802614514573459447456459505
  Share Based Compensation5.9%71.0067.0065.0065.0065.0066.0066.0065.0064.0063.0062.0060.0058.0056.0054.0053.0052.0050.0049.0049.0048.00
Cashflow From Investing0.7%-1,159-1,168-1,189-246-229-222-231-178-158-113-154-168-179-220-346-960-1,075-1,070-864-234-101
Cashflow From Financing-36.8%423669888-263-128-299-397-496-764-886-710-392-317-178-11333658190.00-270-775-1,026
  Dividend Payments1.3%258255252249245241236231227226226226225222218215212209206203199
  Buy Backs-----------------23.0049.0068.0086.0054.00

RMD Income Statement

2023-06-30
Consolidated Statements Of Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Net revenue$ 4,222,993$ 3,578,127$ 3,196,825
Cost of sales (exclusive of amortization shown separately below)1,836,9351,514,1661,312,598
Amortization of acquired intangible assets30,39639,65045,127
Total cost of sales1,867,3311,553,8161,357,725
Gross profit2,355,6622,024,3111,839,100
Operating Expenses [Abstract]   
Selling, general, and administrative874,003737,508670,387
Research and development287,642253,575225,284
Amortization of acquired intangible assets42,02031,07831,078
Restructuring expenses (note 18)9,17708,673
Acquisition related expenses10,9491,8640
Total operating expenses1,223,7911,024,025935,422
Income from operations1,131,8711,000,286903,678
Other income (loss), net:   
Interest (expense) income, net(47,379)(22,312)(23,627)
Loss attributable to equity method investments (note 5)(7,265)(8,486)(11,205)
Gain (loss) on equity investments (note 5)9,922(12,202)14,515
Gain on insurance recoveries20,22700
Other, net(5,712)3,197301
Total other income (loss), net(30,207)(39,803)(20,016)
Income before income taxes1,101,664960,483883,662
Income taxes (note 12)204,108181,046409,157
Net income$ 897,556$ 779,437$ 474,505
Basic earnings per share (note 11) (in dollars per share)$ 6.12$ 5.34$ 3.27
Diluted earnings per share (note 11) (in dollars per share)6.095.303.24
Dividend declared per share (in dollars per share)$ 1.76$ 1.68$ 1.56
Basic shares outstanding (000's) (in shares)146,765146,066145,313
Diluted shares outstanding (000's) (in shares)147,455147,043146,451
Sleep and Respiratory Care products   
Net revenue$ 3,725,017$ 3,177,298$ 2,823,235
Cost of sales (exclusive of amortization shown separately below)1,662,9571,365,4211,177,309
Amortization of acquired intangible assets5,3404,1054,895
Software as a Service   
Net revenue497,976400,829373,590
Cost of sales (exclusive of amortization shown separately below)173,978148,745135,289
Amortization of acquired intangible assets$ 25,056$ 35,545$ 40,232

RMD Balance Sheet

2023-06-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Jun. 30, 2022
Current assets:  
Cash and cash equivalents$ 227,891$ 273,710
Accounts receivable, net of allowances of $23,603 and $23,259 ‎at June 30, 2023 and June 30, 2022, respectively704,909575,950
Inventories (note 3)998,012743,910
Prepaid expenses and other current assets (note 3)437,018337,908
Total current assets2,367,8301,931,478
Non-current assets:  
Property, plant and equipment, net (note 3)537,856498,181
Operating lease right-of-use assets (note 9)127,955132,314
Goodwill (note 4)2,770,2991,936,442
Other intangible assets, net (note 4)552,341345,944
Deferred income taxes (note 12)132,97479,746
Prepaid taxes and other non-current assets262,453171,748
Total non-current assets4,383,8783,164,375
Total assets6,751,7085,095,853
Current liabilities:  
Accounts payable150,756159,245
Accrued expenses (note 6)365,660344,722
Operating lease liabilities, current (note 9)21,91921,856
Deferred revenue138,072108,667
Income taxes payable (note 12)72,22444,893
Short-term debt, net (note 8)9,9029,916
Total current liabilities758,533689,299
Non-current liabilities:  
Deferred revenue119,18695,455
Deferred income taxes (note 12)90,6509,714
Operating lease liabilities, non-current (note 9)116,853120,453
Other long-term liabilities68,1665,974
Long-term debt, net (note 8)1,431,234765,325
Long-term income taxes payable (note 12)37,18348,882
Total non-current liabilities1,863,2721,045,803
Total liabilities2,621,8051,735,102
Commitments and contingencies (note 15)
Stockholders’ equity:  
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued00
Common stock, $0.004 par value, 350,000,000 shares authorized; ‎188,900,583 issued and 147,064,349 outstanding at June 30, 2023 and ‎188,246,955 issued and 146,410,721 outstanding at June 30, 2022588586
Additional paid-in capital1,772,0831,682,432
Retained earnings4,253,0163,613,736
Treasury stock, at cost, 41,836,234 shares at June 30, 2023 and June 30, 2022(1,623,256)(1,623,256)
Accumulated other comprehensive loss(272,528)(312,747)
Total stockholders’ equity4,129,9033,360,751
Total liabilities and stockholders’ equity$ 6,751,708$ 5,095,853

About ResMed